Study Title
A Phase 2/3 Postexposure Prophylaxis Study of PF-07321332/Ritonavir in Household Contacts of a Patient with COVID-19. (Pfizer 1006)
Purpose
To compare the efficacy of 5-day and 10-day regimens of PF-07321332/ritonavir versus placebo in preventing symptomatic RT-PCR+ SARS-CoV-2 infection in adult participants who are household contacts of a patient recently diagnosed with symptomatic Covid 19.
Eligibility
Study Process
Trial Details
Investigator:
Joseph Bocchini, M.D.
IRB:
Advarra Institutional Review Board
IRB Number:
Trial Type:
Drug
Sponsor:
Pfizer
Contact Information: